Rational, computer-enabled peptide drug design: principles, methods, applications and future directions.

Peptides provide promising templates for developing drugs to occupy a middle space between small molecules and antibodies and for targeting 'undruggable' intracellular protein-protein interactions. Importantly, rational or in cerebro design, especially when coupled with validated in silico tools, can be used to efficiently explore chemical space and identify islands of 'drug-like' peptides to satisfy diverse drug discovery program objectives. Here, we consider the underlying principles of and recent advances in rational, computer-enabled peptide drug design. In particular, we consider the impact of basic physicochemical properties, potency and ADME/Tox opportunities and challenges, and recently developed computational tools for enabling rational peptide drug design. Key principles and practices are spotlighted by recent case studies. We close with a hypothetical future case study.

[1]  H. K. Fung,et al.  De novo peptide design with C3a receptor agonist and antagonist activities: theoretical predictions and experimental validation. , 2012, Journal of medicinal chemistry.

[2]  R. Dror,et al.  Long-timescale molecular dynamics simulations of protein structure and function. , 2009, Current opinion in structural biology.

[3]  Erkki Ruoslahti,et al.  De novo design of a tumor-penetrating peptide. , 2013, Cancer research.

[4]  Ri-Bo Huang,et al.  Recent development of peptide drugs and advance on theory and methodology of peptide inhibitor design. , 2015, Medicinal chemistry (Shariqah (United Arab Emirates)).

[5]  Rickey P Hicks,et al.  A brief overview of antimicrobial peptides containing unnatural amino acids and ligand-based approaches for peptide ligands. , 2013, Current topics in medicinal chemistry.

[6]  Belal Chaudhary,et al.  Novel expression of Neuropilin 1 on human tumor-infiltrating lymphocytes in colorectal cancer liver metastases , 2015, Expert opinion on therapeutic targets.

[7]  R. Béliveau,et al.  Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep‐2 , 2008, British journal of pharmacology.

[8]  Meng Wang,et al.  Combination of amino acid/dipeptide with nitric oxide donating oleanolic acid derivatives as PepT1 targeting antitumor prodrugs. , 2014, Journal of medicinal chemistry.

[9]  Nir London,et al.  Rosetta FlexPepDock ab-initio: Simultaneous Folding, Docking and Refinement of Peptides onto Their Receptors , 2011, PloS one.

[10]  Haiyan Jiang,et al.  Increased expression of neuropilin 1 is associated with epithelial ovarian carcinoma. , 2015, Molecular medicine reports.

[11]  Erkki Ruoslahti,et al.  Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs , 2010, Science.

[12]  Chen Jiang,et al.  Targeting Caspase-3 as Dual Therapeutic Benefits by RNAi Facilitating Brain-Targeted Nanoparticles in a Rat Model of Parkinson’s Disease , 2013, PloS one.

[13]  Q. Du,et al.  Two-level QSAR network (2L-QSAR) for peptide inhibitor design based on amino acid properties and sequence positions , 2014, SAR and QSAR in environmental research.

[14]  Premendu P. Mathur,et al.  PepBind: A Comprehensive Database and Computational Tool for Analysis of Protein–peptide Interactions , 2013, Genom. Proteom. Bioinform..

[15]  R. Roberts,et al.  Serum Stable Natural Peptides Designed by mRNA Display , 2014, Scientific Reports.

[16]  Elena B Pasquale,et al.  EphB Receptor-binding Peptides Identified by Phage Display Enable Design of an Antagonist with Ephrin-like Affinity* , 2005, Journal of Biological Chemistry.

[17]  Joshua A. Kritzer,et al.  Peptide Bicycles that Inhibit the Grb2 SH2 Domain , 2012, Chembiochem : a European journal of chemical biology.

[18]  John C Chaput,et al.  Creating protein affinity reagents by combining peptide ligands on synthetic DNA scaffolds. , 2009, Journal of the American Chemical Society.

[19]  Spiros Liras,et al.  Exploring experimental and computational markers of cyclic peptides: Charting islands of permeability. , 2015, European journal of medicinal chemistry.

[20]  François Laviolette,et al.  Machine Learning Assisted Design of Highly Active Peptides for Drug Discovery , 2015, PLoS Comput. Biol..

[21]  Toru Okayama,et al.  Synthesis and Structure−Activity Relationships of an Orally Available and Long-Acting Analgesic Peptide, Nα-Amidino-Tyr-d-Arg-Phe-MeβAla-OH (ADAMB) , 2002 .

[22]  Hugo O. Villar,et al.  Development of an Informatics Platform for Therapeutic Protein and Peptide Analytics , 2013, J. Chem. Inf. Model..

[23]  Matthew P Jacobson,et al.  Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products. , 2015, Journal of medicinal chemistry.

[24]  Siegfried S. F. Leung,et al.  Cell-permeable cyclic peptides from synthetic libraries inspired by natural products. , 2015, Journal of the American Chemical Society.

[25]  Christodoulos A. Floudas,et al.  New Compstatin Peptides Containing N-Terminal Extensions and Non-Natural Amino Acids Exhibit Potent Complement Inhibition and Improved Solubility Characteristics , 2014, Journal of medicinal chemistry.

[26]  Matthew P Jacobson,et al.  Conformational flexibility, internal hydrogen bonding, and passive membrane permeability: successful in silico prediction of the relative permeabilities of cyclic peptides. , 2006, Journal of the American Chemical Society.

[27]  Richard Svensson,et al.  Constrained H-Phe-Phe-NH2 analogues with high affinity to the substance P 1-7 binding site and with improved metabolic stability and cell permeability. , 2013, Journal of medicinal chemistry.

[28]  Matthew T. Weinstock,et al.  Protease‐resistant peptide design—empowering nature's fragile warriors against HIV , 2012, Biopolymers.

[29]  Matthew P. Jacobson,et al.  Predicting and improving the membrane permeability of peptidic small molecules. , 2012, Journal of medicinal chemistry.

[30]  David J. Craik,et al.  Molecular Grafting onto a Stable Framework Yields Novel Cyclic Peptides for the Treatment of Multiple Sclerosis , 2013, ACS chemical biology.

[31]  Roderich D Süssmuth,et al.  Conformational investigation of antibiotic proximicin by X-ray structure analysis and quantum studies suggest a stretched conformation of this type of γ-peptide. , 2013, Bioorganic & medicinal chemistry.

[32]  Avraham Ben-Shimon,et al.  Backbone cyclic peptide inhibitors of protein kinase B (PKB/Akt). , 2011, Journal of medicinal chemistry.

[33]  Julio A Camarero,et al.  Cyclotides, a promising molecular scaffold for peptide‐based therapeutics , 2010, Biopolymers.

[34]  Hiroyuki Nishimori,et al.  Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. , 2011, The Journal of clinical investigation.

[35]  David J Craik,et al.  Cyclotides as grafting frameworks for protein engineering and drug design applications. , 2013, Biopolymers.

[36]  Jürgen Bajorath,et al.  High-resolution view of compound promiscuity , 2013, F1000Research.

[37]  Erkki Ruoslahti,et al.  Tumor-Penetrating Peptides , 2013, Front. Oncol..

[38]  Christodoulos A. Floudas,et al.  De Novo Peptide Design and Experimental Validation of Histone Methyltransferase Inhibitors , 2014, PloS one.

[39]  Donna A Volpe,et al.  Drug-permeability and transporter assays in Caco-2 and MDCK cell lines. , 2011, Future medicinal chemistry.

[40]  Youhua Li,et al.  A general method for making peptide therapeutics resistant to serine protease degradation: application to dipeptidyl peptidase IV substrates. , 2013, Journal of medicinal chemistry.

[41]  Yizhong Zhang,et al.  On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds , 2011, Nature chemical biology.

[42]  Rossella Galati,et al.  Increased Resistance of Peptides to Serum Proteases by Modification of their Amino Groups , 2003, Zeitschrift fur Naturforschung. C, Journal of biosciences.

[43]  Bernhard Y. Renard,et al.  Docking small peptides remains a great challenge: an assessment using AutoDock Vina , 2015, Briefings Bioinform..

[44]  Aleksander S Popel,et al.  Novel peptide-specific quantitative structure-activity relationship (QSAR) analysis applied to collagen IV peptides with antiangiogenic activity. , 2011, Journal of medicinal chemistry.

[45]  Martin S. Taylor,et al.  Toward full-sequence de novo protein design with flexible templates for human beta-defensin-2. , 2008, Biophysical journal.

[46]  C. Campañá,et al.  Clinically Significant Drug Interactions with Cyclosporin An Update , 1996, Clinical pharmacokinetics.

[47]  Alexandre M. J. J. Bonvin,et al.  A Unified Conformational Selection and Induced Fit Approach to Protein-Peptide Docking , 2013, PloS one.

[48]  Stephen W. Fesik,et al.  Discovery of a Potent Stapled Helix Peptide That Binds to the 70N Domain of Replication Protein A , 2014, Journal of medicinal chemistry.

[49]  Haiou Li,et al.  PaFlexPepDock: Parallel Ab-Initio Docking of Peptides onto Their Receptors with Full Flexibility Based on Rosetta , 2014, PloS one.

[50]  Mingdong Huang,et al.  Elucidation of the Contribution of Active Site and Exosite Interactions to Affinity and Specificity of Peptidylic Serine Protease Inhibitors Using Non-Natural Arginine Analogs , 2011, Molecular Pharmacology.

[51]  L. Usvyat,et al.  Anaphylaxis and hypotension after administration of peginesatide. , 2014, The New England journal of medicine.

[52]  Hans J. Vogel,et al.  Serum Stabilities of Short Tryptophan- and Arginine-Rich Antimicrobial Peptide Analogs , 2010, PloS one.

[53]  François Stricher,et al.  PepX: a structural database of non-redundant protein–peptide complexes , 2009, Nucleic Acids Res..

[54]  Pierre Tufféry,et al.  PEP-FOLD: an updated de novo structure prediction server for both linear and disulfide bonded cyclic peptides , 2012, Nucleic Acids Res..

[55]  Erkki Ruoslahti,et al.  Transtumoral targeting enabled by a novel neuropilin-binding peptide , 2012, Oncogene.

[56]  J. Hughes,et al.  Physiochemical drug properties associated with in vivo toxicological outcomes. , 2008, Bioorganic & medicinal chemistry letters.

[57]  Clemencia Pinilla,et al.  Identification of Tetrapeptides from a Mixture Based Positional Scanning Library That Can Restore nM Full Agonist Function of the L106P, I69T, I102S, A219V, C271Y, and C271R Human Melanocortin-4 Polymorphic Receptors (hMC4Rs) , 2014, Journal of medicinal chemistry.

[58]  Gang Li,et al.  Increased expression of neuropilin 1 in melanoma progression and its prognostic significance in patients with melanoma , 2015, Molecular medicine reports.

[59]  Mateusz Kurcinski,et al.  CABS-dock web server for the flexible docking of peptides to proteins without prior knowledge of the binding site , 2015, Nucleic Acids Res..

[60]  Hiroaki Suga,et al.  Construction and screening of vast libraries of natural product-like macrocyclic peptides using in vitro display technologies. , 2015, Current opinion in chemical biology.

[61]  Vikas Nanda,et al.  Empirical estimation of local dielectric constants: Toward atomistic design of collagen mimetic peptides , 2015, Biopolymers.

[62]  C. Heinis,et al.  Phage selection of cyclic peptide antagonists with increased stability toward intestinal proteases. , 2013, Protein engineering, design & selection : PEDS.

[63]  N. Tsomaia Peptide therapeutics: targeting the undruggable space. , 2015, European journal of medicinal chemistry.

[64]  Pierre Tufféry,et al.  PEP-SiteFinder: a tool for the blind identification of peptide binding sites on protein surfaces , 2014, Nucleic Acids Res..

[65]  Haruki Nakamura,et al.  Computer-aided antibody design , 2012, Protein engineering, design & selection : PEDS.

[66]  Rahul Kumar,et al.  TumorHoPe: A Database of Tumor Homing Peptides , 2012, PloS one.

[67]  Minsuk Choi,et al.  A specific STAT3-binding peptide exerts antiproliferative effects and antitumor activity by inhibiting STAT3 phosphorylation and signaling. , 2014, Cancer research.

[68]  Erkki Ruoslahti,et al.  An endocytosis pathway initiated through neuropilin-1 and regulated by nutrient availability , 2014, Nature Communications.

[69]  Sylvia Van Dorpe,et al.  Brainpeps: the blood–brain barrier peptide database , 2012, Brain Structure and Function.

[70]  Bing Gu,et al.  Targeted brain delivery of itraconazole via RVG29 anchored nanoparticles , 2011, Journal of drug targeting.

[71]  Thomas Kodadek,et al.  Quantitative comparison of the relative cell permeability of cyclic and linear peptides. , 2007, Chemistry & biology.

[72]  Nir London,et al.  In silico and in vitro elucidation of BH3 binding specificity toward Bcl-2. , 2012, Biochemistry.

[73]  Fan Yang,et al.  Toxin acidic residue evolutionary function-guided design of de novo peptide drugs for the immunotherapeutic target, the Kv1.3 channel , 2015, Scientific Reports.

[74]  Punit Upadhyaya,et al.  Screening bicyclic peptide libraries for protein-protein interaction inhibitors: discovery of a tumor necrosis factor-α antagonist. , 2013, Journal of the American Chemical Society.

[75]  Nir London,et al.  The structural basis of peptide-protein binding strategies. , 2010, Structure.

[76]  D Altschuh,et al.  A conformation of cyclosporin A in aqueous environment revealed by the X-ray structure of a cyclosporin-Fab complex. , 1992, Science.

[77]  Joost Schymkowitz,et al.  Protein-peptide complex prediction through fragment interaction patterns. , 2013, Structure.

[78]  Kuo-Chen Chou,et al.  Predicting the affinity of epitope-peptides with class I MHC molecule HLA-A*0201: an application of amino acid-based peptide prediction. , 2007, Protein engineering, design & selection : PEDS.

[79]  M. Wood,et al.  Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes , 2011, Nature Biotechnology.

[80]  J. Reichert,et al.  Future directions for peptide therapeutics development. , 2013, Drug discovery today.

[81]  T. Dix,et al.  Development of a Peptide-Derived Orally-Active Kappa-Opioid Receptor Agonist Targeting Peripheral Pain , 2013, The open medicinal chemistry journal.

[82]  Joseph Audie,et al.  Recent work in the development and application of protein-peptide docking. , 2012, Future medicinal chemistry.

[83]  Avraham Ben-Shimon,et al.  AnchorDock: Blind and Flexible Anchor-Driven Peptide Docking. , 2015, Structure.

[84]  Ralf Bergmann,et al.  Rational design of dual peptides targeting ghrelin and Y2 receptors to regulate food intake and body weight. , 2015, Journal of medicinal chemistry.

[85]  Phillip Stafford,et al.  Discovery of High-Affinity Protein Binding Ligands – Backwards , 2010, PloS one.

[86]  R. Dror,et al.  How Fast-Folding Proteins Fold , 2011, Science.

[87]  Kerstin Schmidt,et al.  A Rationally Engineered Anti-HIV Peptide Fusion Inhibitor with Greatly Reduced Immunogenicity , 2012, Antimicrobial Agents and Chemotherapy.

[88]  E. Morgan,et al.  Transferrin and Transferrin Receptor Function in Brain Barrier Systems , 2000, Cellular and Molecular Neurobiology.

[89]  B. Davidson,et al.  Transvascular delivery of small interfering RNA to the central nervous system , 2007, Nature.

[90]  Jianping Wang,et al.  Influence of an unnatural amino acid side chain on the conformational dynamics of peptides. , 2012, Chemphyschem : a European journal of chemical physics and physical chemistry.

[91]  Rhiju Das,et al.  Four Small Puzzles That Rosetta Doesn't Solve , 2011, PloS one.

[92]  L. Walensky,et al.  Hydrocarbon-Stapled Peptides: Principles, Practice, and Progress , 2014, Journal of medicinal chemistry.

[93]  J. Tam,et al.  Orally active peptidic bradykinin B1 receptor antagonists engineered from a cyclotide scaffold for inflammatory pain treatment. , 2012, Angewandte Chemie.

[94]  Spiros Liras,et al.  Improving on nature: making a cyclic heptapeptide orally bioavailable. , 2014, Angewandte Chemie.

[95]  Roberto Improta,et al.  Bond distances in polypeptide backbones depend on the local conformation. , 2015, Acta crystallographica. Section D, Biological crystallography.

[96]  Derek J Richard,et al.  Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer , 2015, Molecular Cancer.

[97]  Bruce Randall Donald,et al.  Computational Design of a PDZ Domain Peptide Inhibitor that Rescues CFTR Activity , 2012, PLoS Comput. Biol..

[98]  T. Hoffmann,et al.  Peptide therapeutics: current status and future directions. , 2015, Drug discovery today.

[99]  Chengfei Yan,et al.  Predicting peptide binding sites on protein surfaces by clustering chemical interactions , 2015, J. Comput. Chem..

[100]  H. K. Fung,et al.  Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework. , 2010, Biophysical journal.

[101]  Zhimin Xiang,et al.  Backbone cyclic peptidomimetic melanocortin-4 receptor agonist as a novel orally administrated drug lead for treating obesity. , 2008, Journal of medicinal chemistry.

[102]  Christodoulos A Floudas,et al.  Derivation of ligands for the complement C3a receptor from the C-terminus of C5a , 2014, European journal of pharmacology.

[103]  Ora Schueler-Furman,et al.  Rosetta FlexPepDock web server—high resolution modeling of peptide–protein interactions , 2011, Nucleic Acids Res..

[104]  Jin Sun,et al.  PepT1, ASBT-Linked Prodrug Strategy to Improve Oral Bioavailability and Tissue Targeting Distribution. , 2014, Current drug metabolism.

[105]  Michel Demeule,et al.  Identification and Design of Peptides as a New Drug Delivery System for the Brain , 2008, Journal of Pharmacology and Experimental Therapeutics.

[106]  K. Chou,et al.  Recent advances in QSAR and their applications in predicting the activities of chemical molecules, peptides and proteins for drug design. , 2008, Current protein & peptide science.

[107]  Hyo-Eon Jin,et al.  Targeting L-type amino acid transporter 1 for anticancer therapy: clinical impact from diagnostics to therapeutics , 2015, Expert opinion on therapeutic targets.

[108]  Channa K. Hattotuwagama,et al.  A Dataset of Experimental HLA-B*2705 Peptide Binding Affinities , 2014 .

[109]  Pascal Tétreault,et al.  Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties. , 2014, The Journal of clinical investigation.

[110]  Yizhong Zhang,et al.  Optimizing PK properties of cyclic peptides: the effect of side chain substitutions on permeability and clearance(). , 2012, MedChemComm.

[111]  Hongmin Li,et al.  Modulation, Bioinformatic Screening, and Assessment of Small Molecular Peptides Targeting the Vascular Endothelial Growth Factor Receptor , 2014, Cell Biochemistry and Biophysics.

[112]  Burak Erman,et al.  VitAL: Viterbi Algorithm for de novo Peptide Design , 2010, PloS one.

[113]  Ernst Schönbrunn,et al.  Structure-based Design of High Affinity Peptides Inhibiting the Interaction of p53 with MDM2 and MDMX* , 2009, The Journal of Biological Chemistry.

[114]  M. Walkinshaw,et al.  X-ray structure of a monomeric cyclophilin A-cyclosporin A crystal complex at 2.1 A resolution. , 1993, Journal of molecular biology.

[115]  David J. Craik,et al.  Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficients , 2014, Proceedings of the National Academy of Sciences.

[116]  R. Doyle,et al.  Oral delivery of the appetite suppressing peptide hPYY(3-36) through the vitamin B12 uptake pathway. , 2011, Journal of medicinal chemistry.

[117]  Nathan Brown,et al.  Multi-objective optimization methods in drug design. , 2013, Drug discovery today. Technologies.

[118]  Annick Thomas,et al.  In silico predictions of 3D structures of linear and cyclic peptides with natural and non‐proteinogenic residues , 2012, Journal of peptide science : an official publication of the European Peptide Society.

[119]  Matthew P Jacobson,et al.  Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers. , 2006, Journal of the American Chemical Society.

[120]  Erkki Ruoslahti,et al.  Tumor-Penetrating iRGD Peptide Inhibits Metastasis , 2014, Molecular Cancer Therapeutics.

[121]  Ryuichi Matsuno,et al.  Relationships between structure and high-throughput screening permeability of peptide derivatives and related compounds with artificial membranes: application to prediction of Caco-2 cell permeability. , 2004, Bioorganic & medicinal chemistry.

[122]  Stefan Wallin,et al.  Exploring Protein-Peptide Binding Specificity through Computational Peptide Screening , 2013, PLoS Comput. Biol..

[123]  Tom C. Karagiannis,et al.  Transferrin Receptor-Mediated Endocytosis: A Useful Target for Cancer Therapy , 2014, The Journal of Membrane Biology.

[124]  Hasup Lee,et al.  GalaxyPepDock: a protein–peptide docking tool based on interaction similarity and energy optimization , 2015, Nucleic Acids Res..

[125]  O. Chepurny,et al.  Synthesis, Characterization and Pharmacodynamics of Vitamin‐B12‐Conjugated Glucagon‐Like Peptide‐1 , 2013, ChemMedChem.